Skip to content
Search

Latest Stories

Boots transfers £4.8 Billion Pension Plan to Legal & General

Boots transfers £4.8 Billion Pension Plan to Legal & General

Boots also brings in an additional payment of around £500m to the scheme

Walgreens Boots Alliance (WBA), which owns the retail pharmacy chain Boots in the UK, has signed a buy-in deal with financial services company Legal & General, transferring its £4.8 billion ($6 billion) pension plan to the latter.


In a release issued on Friday, the company said that the deal is the “largest single transaction of its kind,” in the UK and insures all 53,000 members in the Boots Pension Scheme.

The company said it was the best options to “safeguard members’ benefit against market uncertainty, improved life expectancies and other risks”.

Boots is also bringing in an additional payment of around £500m to the scheme, in addition to the sum (£170m) it has already committed.

Boots Pension Scheme trustee chair Alan Baker is optimistic that this agreement with Legal & General will give “added protection to our members’ long-term benefits by removing market uncertainty and other financial exposures.”

"The scheme will not be reliant on Boots to pay benefits to members and pensions will be protected for decades to come," he added.

L&G will assume the responsibility for issuing individual annuity policies to scheme members and paying benefits directly to them.

However, the business said will take up to two years to complete the process of moving the members, after which it will bear most of the scheme’s economic risk.

Boots UK managing director Seb James commented that they “have fully secured the benefits of all members with a highly respected insurer” and this will provide “greater certainty to both the scheme members and to Boots and is an excellent outcome for both parties."

Describing the deal as their “largest ever single transaction”, Legal & General CEO Kail said it was a proof to their “long-standing relationship with the client.

Earlier, the WBA had agreed to guarantee the scheme but the agreement has been terminated and replaced with a smaller, temporary guarantee.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less